Skip to content

US Guided GNB vs Saline Injection for TKA

A Comparison of Analgesic Efficacy of Ultrasound-Guided Genicular Nerve Block Versus Saline Injection for Total Knee Replacement: a Prospective, Randomized Controlled Trial

Status
Terminated
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03316118
Enrollment
2
Registered
2017-10-20
Start date
2017-10-05
Completion date
2021-06-21
Last updated
2022-09-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Nerve Block, Postoperative Pain, Total Knee Arthroplasty

Keywords

anesthesiology, pain, arthroplasty

Brief summary

Do ultrasound-guided genicular nerve blocks with 0.5% bupivacaine provide improved knee analgesia for patients recovering from total knee replacement surgery compared to saline injection? Hypotheses: The investigators hypothesize that the combination of ultrasound-guided adductor canal block (ACB) and genicular nerve block will achieve lower opioid consumption and therefore lead to decreased systemic side effects and improved overall satisfaction compared to ultrasound-guided saline injection for patients undergoing minimally invasive elective total knee arthroplasty (TKA).

Detailed description

The study medication and protocol will consist of Group 1 (Active) - ultrasound-guided adductor canal blockade with 10 ml of 0.25% bupivacaine and ultrasound-guided genicular nerve blocks with 6 ml of 0.5% bupivacaine, and Group 2 (Control) - ultrasound-guided adductor canal block with 10 ml of 0.25% bupivacaine and ultrasound-guided genicular nerve blocks with 6 ml of normal saline. The surgeon will be blinded to the subjects study arm assignment. An ultrasound-guided ACB will be performed at the level of the mid-thigh of the leg halfway between the superior anterior iliac spine and the patella. The femoral artery, femoral vein, saphenous nerve will be visualized by ultrasonography and the expansion of the adductor canal will be recorded. Sensory assessment of the saphenous distribution will be performed at 30 minutes. The ultrasound-guided genicular nerve block will be performed at the site of the superior lateral, the superior medial, and the inferior medial genicular nerves. The superior lateral genicular nerve is located at the confluence of the lateral femoral shaft and the lateral femoral condyle (in the anteroposterior plane) and at the midpoint of the femur (in the lateral plane). The superior medial genicular nerve site is located at the confluence of the medial femoral shaft and the medial femoral condyle (in the anteroposterior plane) and at the midpoint of the femur (in the lateral plane). The inferior medial genicular nerve site is located at the confluence of the medial tibial shaft and the tibial flare (in the anteroposterior plane) and the midpoint of the tibia (in the lateral plane). Color Doppler will be used to identify the arterial structures which serve as landmarks for the corresponding nerves. All nerve blocks will be performed by a study team physician. Postoperative follow-up will be done by study team member blinded to the group allocation. The dosing of oxycodone/hydrocodone-acetaminophen will be as needed with management goal of a Visual Analog Scale (VAS) score of ≤ 4. Patients with pain not managed by oral agents will receive IV medication. Patients will be visited during their hospital stay every six hours until discharge to record pain scores, opioid consumption, and patient satisfaction. In addition, patients will be given a pain diary to record (VAS) pain scores every six hours until hospital discharge. A study team member will follow up patients by telephone (if discharged prior to) at 48 hours, 72 hours.

Interventions

DRUGbupivacaine

Group 1 will receive genicular nerve block using bupivacaine

DRUGsaline

Group 2 will receive genicular nerve block using normal saline

Sponsors

Northwestern University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
DOUBLE (Subject, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
40 Years to 85 Years
Healthy volunteers
No

Inclusion criteria

* Participants 40 to 85 years old who are presenting for minimally invasive total knee arthroplasty under spinal anesthesia and are candidates for peripheral nerve blocks. * Minimally invasive is defined as custom modified instrumentation, a quadriceps sparing arthrotomy that does not extend beyond 1cm proximal to the patella and surgical techniques that focus on soft tissue protection.

Exclusion criteria

* Patient refusal * American Society of Anesthesiologists physical status classification of 4 or higher * Pre-existing neuropathy in the femoral or sciatic distribution * Coagulopathy * Infection at the site * Chronic opioid use (greater than 3 months) * Pregnancy * Medical conditions limiting physical therapy participation * Any other contra-indication to regional anesthesia

Design outcomes

Primary

MeasureTime frameDescription
Post-operative Opioid Consumption During the Hospital Stay36 hours after surgeryPost-operative opioid consumption measured in morphine milligram equivalents (MME)during the hospital stay up to 36 hours after surgery.

Secondary

MeasureTime frameDescription
Mean Pain Scores of the Knee at Rest for the First 48 Hours After Surgery48 hours after surgeryMean pain scores post operative reported using the VAS (visual analog scale) for knee pain at rest on a scale of 0 (no pain to 10 worst pain imaginable). This will be assessed every 6 hours up to 48 hours with the visual analog scale where 0 equals no pain and 10 represents excruciating pain.
Overall Satisfaction With Pain Control 72 Hours After Surgery72 hours after surgeryOverall satisfaction with pain control 72 hours after surgery using a visual analog scale where 0 = not satisfied and 10 being extremely satisfied
Length of HospitalizationAdmission to discharge from hospitalLength of hospitalization in hours from time to admission to time of discharge.

Countries

United States

Participant flow

Participants by arm

ArmCount
Group 1
Patient will receive genicular nerve block with bupivacaine bupivacaine: Group 1 will receive genicular nerve block using bupivacaine
2
Group 2
Patient will receive normal saline as the nerve block saline: Group 2 will receive genicular nerve block using normal saline
0
Total2

Baseline characteristics

CharacteristicTotalGroup 1
Age, Continuous71.5 Years71.5 Years
Height Inches66.5 Inches66.5 Inches
Kilograms (kG) weight95.8 Kilograms95.8 Kilograms
Pre Surgical Baseline Pain at Rest3 Units on a scale3 Units on a scale
Race (NIH/OMB)
American Indian or Alaska Native
0 Participants0 Participants
Race (NIH/OMB)
Asian
0 Participants0 Participants
Race (NIH/OMB)
Black or African American
0 Participants0 Participants
Race (NIH/OMB)
More than one race
0 Participants0 Participants
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
0 Participants0 Participants
Race (NIH/OMB)
Unknown or Not Reported
0 Participants0 Participants
Race (NIH/OMB)
White
2 Participants2 Participants
Region of Enrollment
United States
2 participants2 participants
Sex: Female, Male
Female
2 Participants2 Participants
Sex: Female, Male
Male
0 Participants0 Participants

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
deaths
Total, all-cause mortality
0 / 20 / 0
other
Total, other adverse events
1 / 20 / 0
serious
Total, serious adverse events
0 / 20 / 0

Outcome results

Primary

Post-operative Opioid Consumption During the Hospital Stay

Post-operative opioid consumption measured in morphine milligram equivalents (MME)during the hospital stay up to 36 hours after surgery.

Time frame: 36 hours after surgery

Population: Only two subjects enrolled both were randomized to group 1.

ArmMeasureValue (MEAN)
Group 1Post-operative Opioid Consumption During the Hospital Stay24.17 Morphine milligram equivalents (MME)
Secondary

Length of Hospitalization

Length of hospitalization in hours from time to admission to time of discharge.

Time frame: Admission to discharge from hospital

Population: Study was terminated early due to low enrollment. No subjects were randomized to group 2.

ArmMeasureValue (MEAN)
Group 1Length of Hospitalization38.29 Elapsed time in hours
Secondary

Mean Pain Scores of the Knee at Rest for the First 48 Hours After Surgery

Mean pain scores post operative reported using the VAS (visual analog scale) for knee pain at rest on a scale of 0 (no pain to 10 worst pain imaginable). This will be assessed every 6 hours up to 48 hours with the visual analog scale where 0 equals no pain and 10 represents excruciating pain.

Time frame: 48 hours after surgery

Population: Study terminated due to low enrollment. No subjects randomized to group 2.

ArmMeasureValue (MEAN)
Group 1Mean Pain Scores of the Knee at Rest for the First 48 Hours After Surgery3.05 score on a scale
Secondary

Overall Satisfaction With Pain Control 72 Hours After Surgery

Overall satisfaction with pain control 72 hours after surgery using a visual analog scale where 0 = not satisfied and 10 being extremely satisfied

Time frame: 72 hours after surgery

Population: Study terminated early due to low enrollment. No subjects were randomized to group 2.

ArmMeasureValue (MEAN)
Group 1Overall Satisfaction With Pain Control 72 Hours After Surgery7 score on a scale

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026